ITEOS THERAPEUTICS INC (ITOS) Stock News
NASDAQ:ITOS - Nasdaq - US46565G1040 - Common Stock - Currency: USD
ITOS Latest News, Press Relases and Analysis
These stocks are gapping in today's session
Let's have a look at the gap up and gap down stocks in today's session.
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’
The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended.
iTeos Therapeutics Announces Its Intention to Wind Down Operations
iTeos Therapeutics Announces Its Intention to Wind Down Operations
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring...
Citi sells Polish consumer business to VeloBank
Upon closing, it will be the 10th international consumer business Citi has sold since 2021. The bank will maintain its institutional business in Poland, as it has elsewhere, following the sale.
Cancer drugmaker iTeos to shut down
Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid to "maximize" shareholder value.
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
Is GSK plc (GSK) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?
We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Trump Incentivizes Pharmaceuticals to Build Domestic Manufacturing Capacity […]
iTeos verkündet Topline-Zwischenergebnisse der GALAXIES Lung-201-Studie für die First-Line-Behandlung mit Belrestotug und Dostarlimab von Krebspatienten, die von einem nicht-kleinzelligen Lungenkarzinom mit hoher PD-L1-Expression betroffen sind
– GALAXIES Lung-201 erfüllte nicht die festgelegten Kriterien für klinisch bedeutsame Verbesserungen beim progressionsfreien Überleben – Ausgehend von der...
iTeos annonce les premiers résultats provisoires de l’étude GALAXIES Lung-201 portant sur l’association belrestotug + dostarlimab en traitement de première intention des patients atteints d’un cancer du poumon non à petites cellules et présentant un taux
– L’étude GALAXIES Lung-201 n’a pas satisfait aux critères établis pour une amélioration cliniquement significative de la survie sans progression – Sur la...
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish
The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.
GSK, iTeos End Development of Experimental Lung Cancer Drug
GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks for a new generation of immunotherapy medicines.
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data,...
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
iTeos meldet Finanzergebnisse für das erste Quartal 2025 und gibt aktuelle Geschäftsinformationen bekannt
- Topline-Zwischenergebnisse von GALAXIES Lung-201 mit >240 Patienten im 2. Quartal 2025 erwartet - Zwischenergebnisse von GALAXIES H&N-202 und...
iTeos publie les résultats financiers de son premier trimestre 2025 et fait le point sur ses activités
- Données de haut niveau provisoires issues de l’essai GALAXIES Lung-201, et plus de 240 patients attendus au deuxième trimestre 2025 - Données...
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006...
iTeos präsentiert präklinische Daten zu EOS-215 – dem potenziellen Best-in-Class-Antikörper gegen TREM2 und neuartigen PTPN1/2-Inhibitor – auf der Jahrestagung 2025 der American Association for Cancer Research
WATERTOWN, Mass. und GOSSELIES, Belgien, March 26, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), ein biopharmazeutisches Unternehmen...
iTeos présentera les données précliniques d’EOS-215, un anticorps anti-TREM2 supposé meilleur de sa catégorie, et d’un nouvel inhibiteur de PTPN1/2 lors de l’édition 2025 du congrès annuel de l’American Association for Cancer Research
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 26 mars 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique...
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...
iTeos gibt Geschäftsergebnisse für das vierte Quartal und das Gesamtjahr 2024 sowie Unternehmensneuigkeiten bekannt
- Topline-Zwischendatensatz von GALAXIES Lung-201 mit >240 Patienten für das 2. Quartal 2025 erwartet - Zwischendatensätze von GALAXIES H&N-202 und...
iTeos fait le point sur ses activités et publie ses résultats financiers pour le quatrième trimestre et l’exercice 2024
- Données provisoires de haut niveau issues de l’étude GALAXIES Lung-201 portant sur plus de 240 patients prévues pour le 2ᵉ trimestre 2025- Données...
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC...
iTeos annonce ses priorités stratégiques et ses étapes clés prévues pour 2025
- Plusieurs extractions de données cliniques issues du programme TIGIT attendues en 2025, portant sur plus de 400 patients issus de deux essais de Phase II...
iTeos gibt strategische Prioritäten und erwartete Meilensteine für 2025 bekannt
- Im Laufe des Jahres 2025 werden mehrere im Rahmen des TIGIT-Programms durchgeführte Analysen klinischer Daten erwartet, darunter jene zu > 400...